02 September 2020

The pandemic has led to huge disruption in clinical trials which will have a significant impact on innovative drug pipelines.

During this hour long panel discussion, Senior Partners, Paul Branthwaite and Phil Barrington join other heath care professionals to discuss the criteria which shapes clinical trial site selection and whether they will differ post COVID-19.

Facilitated by:
- Karen O'Hanlon, Boyd Consultants Limited

Speakers included:
- Edward Littler, ReViral Ltd
- Nele Langenaken Cerba Research
- Paul Branthwaite, tranScrip
- Phil Barrington, tranScrip

You can view all One Nucleus' recordings here.